ACL.AU Australian Clinical Labs Ltd

Healthcare Health Care Providers & Services Australian Securities Exchange
3.30 AUD
Close of Nov 1, 2026
1.77 3.32
Market cap
AUD 616M
P/E
27.5x
P/B
4.12x
ROE
15.9%
Dividend yield
4.00%
Fundamental score
1.4/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is ACL.AU undervalued?

Graham number
Price3.30
Graham value1.47
Premium124.3%

ACL.AU trades 124.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Australian Clinical Labs Ltd fundamental analysis

7 of 22 checks passed

ROE 1/2

Moderate return on equity (15.9%), between 10% and 20%.

ROA 1/1

Return on assets (4.0%) is above the industry median (-0.3%).

Profit Consistency 2/2

Profitable for 7 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (-27.7%) is not above the 5-year average (-20.9% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (-27.7%) is below the industry median (-1.5%).

Revenue Growth 1/2

Revenue grew 1.8% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

High debt to equity (225.7%), above 100%.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 0/1

EBIT is 3.3x against interest expense, below 5x.

PE vs Market 0/1

PE (27.5x) is above the market median (15.0x).

PE vs Industry 0/1

PE (27.5x) is above the industry median (27.1x).

PBV 0/1

Price to book (4.1x) is above the industry median (2.0x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 113.2, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (4.0%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

Payout ratio is 103.7%, above 90% of earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Australian Clinical Labs Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Australian Clinical Labs Ltd

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers cardiac testing, gastroenterology, haematology, chemical pathology, antenatal testing, serology and microbiology, cervical screening, commercial drug and alcohol testing, STI Testing, veterinary pathology, molecular cancer services, clinical trials pathology, advanced genetic testing, functional pathology, histopathology and cytopathology, CPD education programs for clini…

Full company profile